Upadacitinib in children with moderate to severe Crohn's disease
Treatments studied
Part of Digestive system clinical trials.
This study tests an oral pill called upadacitinib for children with moderate to severe Crohn's disease that hasn't responded well to other treatments. It aims to see if the medicine can reduce inflammation and improve symptoms safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Child must weigh at least 22 pounds (10 kg) at the start.
- Crohn's disease must be moderate to severe, confirmed by a scope showing active inflammation.
- Other Crohn's treatments (steroids, immune pills, or biologics) must have failed, been poorly tolerated, or not safe to use.
- Child must not have certain Crohn's complications like active abscesses, narrow bowel segments, or more than 3 prior bowel surgeries.
- Child must not have ulcerative colitis, a genetic bowel disease, or a condition that affects medicine absorption.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medication called upadacitinib for people with inflammatory bowel disease (ulcerative colitis or Crohn's). The goal is to see how well it works and if it's safe.
This study is for people with moderate to severe Crohn's disease who are starting a medication called upadacitinib. Researchers will watch how the disease changes over time and check for any side effects. It's an observational study, meaning you'll keep getting your regular treatment.
This study tests two oral/ injectable medicines (upadacitinib and risankizumab) in adults with moderate-to-severe Crohn's who have already tried a TNF-blocker. It aims to see how well these treatments work in everyday practice.
This study tests a new medicine called risankizumab for children with moderate to severe Crohn's disease. It is given as an IV infusion or a shot under the skin to see if it can reduce inflammation and improve symptoms.
This trial tests combining two medicines, vedolizumab and upadacitinib, to see if they work better together than vedolizumab alone for people with moderate to severe Crohn's disease that hasn't responded well to other treatments.
This study tests a new targeted therapy for adults with moderate to severe Crohn's disease who haven't responded well to other treatments. It aims to reduce inflammation and improve symptoms.
Hear when a new Crohn’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.